Patent ID: 11896616
Assignee: NATIONAL UNIVERSITY OF SINGAPORE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 6:
7. A genetically engineered cell population that does not express major histocompatibility complex (MHC) I molecules,
wherein said genetically engineered cell population is derived from K562 cells,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 is encoded by a nucleic acid sequence that comprises SEQ ID NO: 1,
wherein said genetically engineered cell population is modified to express membrane-bound 4-1BB ligand (mb4-1BBL) comprising the amino acid sequence of SEQ ID NO: 14,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-18 (mbIL18), wherein the mbIL18 comprises the amino acid sequence of SEQ ID NO: 8,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12A (IL12A), wherein the mbIL12A comprises the amino acid sequence of SEQ ID NO: 4,
wherein said genetically engineered cell population is modified to express membrane-bound interleukin-12B (IL12B), wherein the mbIL12B comprises the amino acid sequence of SEQ ID NO: 6,
wherein said genetically engineered cell population does not express major histocompatibility complex (MHC) I molecules, and
wherein co-culture of said genetically engineered cell population with a population of natural killer (NK) cells results in the activation and expansion of the NK cells.